Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.

Morfini M, Gherardini S.

Ther Adv Hematol. 2018 Jun;9(6):149-162. doi: 10.1177/2040620718774258. Epub 2018 Jun 5. Review.

2.

Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?

Tasian SK.

Ther Adv Hematol. 2018 Jun;9(6):135-148. doi: 10.1177/2040620718774268. Epub 2018 May 17. Review.

3.

The evolution of stem-cell transplantation in multiple myeloma.

Mahajan S, Tandon N, Kumar S.

Ther Adv Hematol. 2018 May;9(5):123-133. doi: 10.1177/2040620718761776. Epub 2018 Mar 5. Review.

4.

Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.

DeStefano CB, Hourigan CS.

Ther Adv Hematol. 2018 May;9(5):109-121. doi: 10.1177/2040620718761778. Epub 2018 Mar 27. Review.

5.

Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Shindiapina P, Alinari L.

Ther Adv Hematol. 2018 Apr;9(4):89-105. doi: 10.1177/2040620718761777. Epub 2018 Mar 5. Review.

6.

Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant.

Allen J, Ruano Mendez AL, Rybicki L, Sawalha Y, Jagadeesh D, Dean R, Pohlman B, Smith MR, Hsi ED, Hill BT.

Ther Adv Hematol. 2018 Apr;9(4):81-87. doi: 10.1177/2040620718759249. Epub 2018 Mar 29.

7.

Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.

Kuo CY, Wang PN, Hwang WL, Tzeng CH, Bai LY, Tang JL, Chang MC, Lin SF, Chen TY, Chen YC, Tan TD, Hsieh CY, Lin C, Lai C, Miljkovic D, Chang CS.

Ther Adv Hematol. 2018 Mar;9(3):65-78. doi: 10.1177/2040620718756603. Epub 2018 Mar 4.

8.

Novel therapies and current clinical progress in hemophilia A.

Balkaransingh P, Young G.

Ther Adv Hematol. 2018 Feb;9(2):49-61. doi: 10.1177/2040620717746312. Epub 2017 Dec 28. Review.

9.

New and emerging therapies for acute and chronic graft versus host disease.

Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E.

Ther Adv Hematol. 2018 Jan;9(1):21-46. doi: 10.1177/2040620717741860. Epub 2017 Nov 28. Review.

10.

Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Itchaki G, Brown JR.

Ther Adv Hematol. 2018 Jan;9(1):3-19. doi: 10.1177/2040620717741861. Epub 2017 Nov 28. Review.

11.

The role of oral anticoagulant therapy in patients with acute coronary syndrome.

Moon JY, Nagaraju D, Franchi F, Rollini F, Angiolillo DJ.

Ther Adv Hematol. 2017 Dec;8(12):353-366. doi: 10.1177/2040620717733691. Epub 2017 Oct 13. Review.

12.

Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date.

Giansily-Blaizot M, Schved JF.

Ther Adv Hematol. 2017 Dec;8(12):345-352. doi: 10.1177/2040620717737701. Epub 2017 Nov 3. Review.

13.

The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.

Wang TP, Scott JH, Barta SK.

Ther Adv Hematol. 2017 Dec;8(12):329-344. doi: 10.1177/2040620717738740. Epub 2017 Nov 22. Review.

14.

Biological and clinical implications of telomere dysfunction in myeloid malignancies.

Kishtagari A, Watts J.

Ther Adv Hematol. 2017 Nov;8(11):317-326. doi: 10.1177/2040620717731549. Epub 2017 Oct 6. Review.

15.

Corrigendum.

[No authors listed]

Ther Adv Hematol. 2017 Sep;8(9):273. doi: 10.1177/2040620717733591. Epub 2017 Sep 9.

16.

Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A.

Fosbury E, Drebes A, Riddell A, Chowdary P.

Ther Adv Hematol. 2017 Sep;8(9):263-272. doi: 10.1177/2040620717720861. Epub 2017 Aug 3. Review.

17.

Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Gallogly MM, Lazarus HM, Cooper BW.

Ther Adv Hematol. 2017 Sep;8(9):245-261. doi: 10.1177/2040620717721459. Epub 2017 Aug 19. Review.

18.

Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.

Eskazan AE, Keskin D.

Ther Adv Hematol. 2017 Sep;8(9):237-243. doi: 10.1177/2040620717719851. Epub 2017 Jul 25. Review.

19.

Current and emerging factor VIII replacement products for hemophilia A.

Cafuir LA, Kempton CL.

Ther Adv Hematol. 2017 Oct;8(10):303-313. doi: 10.1177/2040620717721458. Epub 2017 Aug 26. Review.

20.

Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.

Nikolaenko L, Chen R, Herrera AF.

Ther Adv Hematol. 2017 Oct;8(10):293-302. doi: 10.1177/2040620717728000. Epub 2017 Aug 29. Review.

Supplemental Content

Loading ...
Support Center